Author(s):
Charanjit Kaur, Navjeet Kaur, Deepika Sharma, Gurvinder Singh, Narinderpal Singh, Viney, Sachin Kumar Singh, Vrinderpal Singh, Rajesh Kumar
Email(s):
rajksach09@gmail.com
DOI:
10.52711/0974-360X.2021.00599 
Address:
Charanjit Kaur1, Navjeet Kaur2, Deepika Sharma3, Gurvinder Singh3, Narinderpal Singh4, Viney4, Sachin Kumar Singh3, Vrinderpal Singh3, Rajesh Kumar3*
1Khalsa College of Pharmacy, Amritsar, Punjab, India.
2Rayat Bahra Institute of Pharmacy, Hoshiarpur, Punjab, India.
3*School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
4Herbal Health Consortium Private Ltd., Amritsar, Punjab, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 6,
Year - 2021
ABSTRACT:
Sertaconazole is an imidazole/triazole type antifungal agent which selectively inhibit fungal cytochrome P450 sterol C-14 a-demethylase and act as potent antifungal agent. This enzyme is essential for fungal cell wall synthesis as it converts lanosterol to ergosterol. The antifungal spectrum of drug includes Candida, Malassezia, Cryptococcus, Aspergillus, Scopulariopsis and Scedosporium. In addition, sertaconazole has been reported to exhibit an antimicrobial activity against staphylococci, streptococci, and protozoa. The drug is practically insoluble in water and has an apparent half-life of approximately 60 hrs. It is prescribed for the treatment of interdigital tinea pedis (topical), mycoses of skin and mucosa in dermatology and gynaecology. Sertaconazole penetrates the horny layer of skin and the therapeutic concentrations may be found after a long period of time, avoiding the potential risk of systemic absorption. It is available in the market as cream, lotion and tablet formulations. This review summarises the physiochemical characterization of drug, involved pharmacokinetic, pharmacodynamics, safety profile along with the reported preclinical, clinical and formulation studies and patents thereof and the paradigm shift in the use of sertaconazole.
Cite this article:
Charanjit Kaur, Navjeet Kaur, Deepika Sharma, Gurvinder Singh, Narinderpal Singh, Viney, Sachin Kumar Singh, Vrinderpal Singh, Rajesh Kumar. An Updated Review of What, When and How of Sertaconazole: A Potent Antifungal Agent. Research Journal of Pharmacy and Technology. 2021; 14(6):3441-8. doi: 10.52711/0974-360X.2021.00599
Cite(Electronic):
Charanjit Kaur, Navjeet Kaur, Deepika Sharma, Gurvinder Singh, Narinderpal Singh, Viney, Sachin Kumar Singh, Vrinderpal Singh, Rajesh Kumar. An Updated Review of What, When and How of Sertaconazole: A Potent Antifungal Agent. Research Journal of Pharmacy and Technology. 2021; 14(6):3441-8. doi: 10.52711/0974-360X.2021.00599 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-6-89
REFERENCES:
1. Eggimann PGJ, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 3(11): 2003: 685-702.
2. Raga MM, Moreno-Manas M, Cuberes MR, Palacin C, Castello JM, Ortiz JA. Synthesis and antimycotic activity of (benzo[b]thienyl)methyl ethers of 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-ethanol and of (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone oxime. Arzneimittelforschung. 42(5A): 1992: 691-694.
3. Albet C, Fernández JM, Sacristán A, Ortiz JA. Physico-chemical properties, analytical determinations and stability of sertaconazole nitrate. Arzneimittelforschung. 42(5A): 1992: 695-698.
4. https://www.drugbank.ca/drugs/DB01153#taxonomy
5. Agut J, Palacín C, Sacristán A, Ortiz JA. Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneimittelforschung. 42(5A): 1992: 718-720.
6. Agut J, Palacín C, Salgado J, Casas E, Sacristán A, Ortiz JA. Direct membrane- damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimittelforschung. 42(5A): 1992: 721-724.
7. Sur R, Babad JM, Garay M, Liebel FT, Southall MD. Anti-Inflammatory Activity of Sertaconazole Nitrate Is Mediated via Activation of a p38-COX-2-PGE2 Pathway. Journal of Investigative Dermatology. 128(2): 2008: 336-344.
8. Agut J, Moren M, Rego M, Sacristán A, Ortiz JA. Pharmacokinetic evaluation of labelled sertaconazole after dermal application. Arzneimittelforschung. 42(5A): 1992: 748-751.
9. Farré M, Ugena B, Badenas JM, Márquez M, Roset P, Ortiz JA. Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration. Arzneimittelforschung. 42(5A): 1992: 752-754.
10. Palacin C, Tarrago C, Sacristan A, Ortiz J. A Antifungal activity of sertaconazole in the cutaneous retention time test. Journal of medical mycology. 5(1): 1995: 35-39.
11. Croxtall JD, Plosker GL. Sertaconazole- A Review of Its Use in the Management of Superficial Mycoses in Dermatology and Gynaecology. Drugs. 69(3): 2009: 339-359.
12. Umbert P, Nasarre J, Bello A, Herrero E, Roset P, Márquez M, Torres J, Ortiz JA. Phase II study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candida albicans. Arzneimittelforschung. 42(5A): 1992: 757-760.
13. Grau MT, Romero A, Sacristán A, Ortiz JA. Acute toxicity studies of sertaconazole. Arzneimittelforschung. 42(5A): 1992: 725-726.
14. Romero A, Grau MT, Villamayor F, Sacristán A, Ortiz JA. Reproduction toxicity of sertaconazole. Segment II (teratology) and segment III (peri-postnatal toxicity). Arzneimittelforschung. 42(5A): 1992: 739-742.
15. Romero A, Villamayor F, Grau MT, Sacristán A, Ortiz JA. Chronic toxicity studies of sertaconazole after oral administration to rats and ferrets. Arzneimittelforschung. 42(5A): 1992: 732-738.
16. Romero A, Villamayor F, Grau MT, Sacristán A, Ortíz JA. Subacute toxicity and maximum tolerable dose of sertaconazole in repeated administration studies. Arzneimittelforschung. 42(5A): 1992: 727-732.
17. Grau MT, Romero A, Sacristán A, Ortiz JA. Dermal tolerance and phototoxicity studies of sertaconazole. Arzneimittelforschung. 42(5A): 1992: 746-747.
18. Van Esso D, Fajo G, Losada I, Vilallonga M, Casanovas JM, Clanxet J, Aliaga A. Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections. Clinical Therapeutics. 17(2): 1995: 264-269.
19. Borelli C, Klövekorn G, Ernst TM, Bödeker RH, Korting HC, Neumeister C. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigi- talis, or a corresponding candidosis. Am J Clin Dermatol. 8(6): 2007: 371-378.
20. Drouhet E, Dupont B. In vitro antifungal activity of sertaconazole. Arzneimittelforschung. 42(5A): 1992: 705-710.
21. Romaguera C, Herrero E, Márquez M, Torres J, Ortiz JA. Study on the sensitizing capacity of the new antimycotic sertacona- zole in the treatment of cutaneous mycoses. Arzneimittelforschung. 42(5A): 1992: 754-756.
22. Wang PH, Chao HT, Chen CL, Yuan CC. Single-dose Sertaconazole Vaginal Tablet Treatment of Vulvovaginal Candidiasis. J Chin Med Assoc. 69(6): 2006: 259-263.
23. Balighi K, Ghodsi SZ, Daneshpazhooh M, Ghale-Baghi S, Nasimi M, Azizpoura A. Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial. Int J Women's Dermatol. 3(2): 2017: 107-110.
24. Choudhary S, Bisati S, Singh A, Koley S. Efficacy and Safety of Terbinafine Hydrochloride 1% Cream vs. Sertaconazole Nitrate 2% Cream in Tinea Corporis and Tinea Cruris: A Comparative Therapeutic Trial. Ind J Dermatol. Indian J Dermatol. 58(6): 2013: 457-460.
25. Susilo R, Korting HC, Strauss UP, Menke G, Schuster O, Menke A. Rate and extent of percutaneous absorption of sertaconazole nitrate after topical administration. Arzneimittelforschung. 55(6): 2005: 338-342.
26. Quereux C1, Gelas B, Chevallier T, Petit F, Micheletti MC. Evaluation of the efficacity and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis. Gynecol Obstet Fertil. 28(3): 2000: 238-244.
27. Dellenbach P, Thomas JL, Guerin V, Ochsenbein E, Contet-Audonneau N. Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int J Gynaecol Obstet. 71: 2000: S47-S52.
28. Susilo R, Korting HC, Greb W, Strauss UP. Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation. Am J Clin Dermatol. 7(4): 2006: 259-262.
29. Goldust M, Rezaee E, Raghifar R. Treatment of seborrheic dermatitis: comparison of sertaconazole 2% cream versus pimecrolimus 1% cream. Irish J Med Sci. 182(4): 2013: 703-706.
30. Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of seborrheic dermatitis: the efficiency of sertaconazole 2% cream vs. tacrolimus 0.03% cream. Ann Parasitol. 59(2): 2013: 73-77.
31. Sharma A, Saple DG, Surjushe A, Rao GR, Kura M, Ghosh S, Bolmall C, Baliga V. Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. Mycoses. 54(3): 2011: 217-222.
32. Ständer S, Metz M, Ramos F MH, Maurer M, Schoepke N, Tsianakas A, Zeidler C, Luger TA. Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability. Acta Derm Venereol. 96(6): 2016: 792-796.
33. Younes NF, Abdel-Halim SA, Elassasy AI. Corneal targeted Sertaconazole nitrate loaded cubosomes: Preparation, statistical optimization, in vitro characterization, ex vivo permeation and in vivo studies. International Journal of Pharmaceutics. 553(1-2): 2018: 386-397.
34. Sahoo S, Pani NR, Sahoo SK. Microemulsion based topical hydrogel of sertaconazole: Formulation, characterization and evaluation. Colloids and Surfaces B: Biointerfaces. 120: 2014: 193-199.
35. Moammal S. Qurt İE, Seher Birteksöz Tan, Meryem Sedef Erdal, Ahmet Araman, Sevgi Güngör. Voriconazole and sertaconazole loaded colloidal nano-carriers for enhanced skin deposition and improved topical fungal treatment. J Drug Del Sci Technol. 48: 2018: 215-222.
36. Abdellatif MM, Khalil IA, Khalil MAF. Sertaconazole nitrate loaded nanovesicular systems for targeting skin fungal infection: In-vitro, ex-vivo and in-vivo evaluation. Int J Pharmaceutics. 527(1-2): 2017: 1-11.
37. Pande VV, Kadnor NA, Kadam RN, Upadhye SA. Fabrication and Characterization of Sertaconazole Nitrate Microsponge as a Topical Drug Delivery System. Indian J Pharm Sci. 77(6): 2015: 675-680.
38. Mandlik SK, Siras SS, Birajdar KR. Optimization and characterization of sertaconazole nitrate flexisomes embedded in hydrogel for improved antifungal activity. J Liposome Res. 29(1): 2019: 10-20.
39. https://patents.google.com/patent/US5135943